There is a race underway to develop treatments for the fatty liver disease known as NASH. And for good reason — with a massive patient population and no treatments approved yet, there is money to be made.

But the companies in this race are not all built alike. The EASL liver disease research meeting, which was just held in Vienna, Austria, however, offers an opportunity to step back and sentiment-check the stature and status of the five most prominent NASH contenders.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One of the essential purposes of Phase 2 is to explore potential clinical endpoints for Phase 3. Post-hoc analysis is a normal part of this process to understand the patient subpopulation where the drug has benefit (level of fibrosis etc.) I do not understand the author’s view that a drug is flawed simply because it is following the process — exactly what Phase 2 is intended to discover.

  • Why are you so skeptical about Genfits GNFT Elafibranor? Ok there was a retrospective analysis for the scope of the ph3 study but nevertheless Elafibranor is very advanced and there is a chance in the interim analysis to file for conditional approval. Compared with all other NASH stocks GNFT looks really cheap with a market capitalization under to 1 billion.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy